JUPITER: Rosuvastatin Reduced Risk For Venous Thromboembolism

Cardiology Today -- Apparently healthy adults assigned to daily rosuvastatin therapy experienced a 43% risk reduction in the occurrence of venous thromboembolism, according to a subgroup analysis of the JUPITER trial.